This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hrncic, R. Articles by Solomon, A. Search for Related Content PubMed PubMed Citation Articles by Hrncic, R. Articles by Solomon, A.

(American Journal of Pathology. 2000;157:1239-1246.)
© 2000 American Society for Investigative Pathology

Regular Articles

Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits

From the Human Immunology and Cancer Program, Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee

Primary light-chain-associated (AL) amyloidosis is characterized by the deposition in tissue of monoclonal light chains as fibrils. With rare exception, this process is seemingly irreversible and results in progressive organ dysfunction and eventually death. To determine whether immune factors can effect amyloid removal, we developed an experimental model in which mice were injected with amyloid proteins extracted from the spleens or livers of patients with AL amyloidosis. Notably, the resultant amyloidomas were rapidly resolved, as compared to controls, when animals received injections of an anti-light-chain monoclonal antibody having specificity for an amyloid-related epitope. The reactivity of this monoclonal antibody was not dependent on the V_L or C_L isotype of the fibril, but rather seemed to be directed toward a ß-pleated sheet conformational epitope expressed by AL and other amyloid proteins. The amyloidolytic response was associated with a pronounced infiltration of the amyloidoma with neutrophils and putatively involved opsonization of fibrils by the antibody, leading to cellular activation and release of proteolytic factors. The demonstration that AL amyloid resolution can be induced by passive administration of an amyloid-reactive antibody has potential clinical benefit in the treatment of patients with primary amyloidosis and other acquired or inherited amyloid-associated disorders.

This article has been cited by other articles:

				M. J. Gunzburg, M. A. Perugini, and G. J. Howlett Structural Basis for the Recognition and Cross-linking of Amyloid Fibrils by Human Apolipoprotein E J. Biol. Chem., December 7, 2007; 282(49): 35831 - 35841. [Abstract] [Full Text] [PDF]

				G. Habicht, C. Haupt, R. P. Friedrich, P. Hortschansky, C. Sachse, J. Meinhardt, K. Wieligmann, G. P. Gellermann, M. Brodhun, J. Gotz, et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing A protofibrils PNAS, December 4, 2007; 104(49): 19232 - 19237. [Abstract] [Full Text] [PDF]

				J. S. Wall, S. J. Kennel, M. Paulus, J. Gregor, T. Richey, J. Avenell, J. Yap, D. Townsend, D. T. Weiss, and A. Solomon Radioimaging of Light Chain Amyloid with a Fibril-Reactive Monoclonal Antibody J. Nucl. Med., December 1, 2006; 47(12): 2016 - 2024. [Abstract] [Full Text] [PDF]

				L. M. Dember Amyloidosis-Associated Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3458 - 3471. [Abstract] [Full Text] [PDF]

				V. Sanchorawala Light-Chain (AL) Amyloidosis: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1331 - 1341. [Abstract] [Full Text] [PDF]

				B. O'Nuallain, R. Hrncic, J. S. Wall, D. T. Weiss, and A. Solomon Diagnostic and Therapeutic Potential of Amyloid-Reactive IgG Antibodies Contained in Human Sera. J. Immunol., June 1, 2006; 176(11): 7071 - 7078. [Abstract] [Full Text] [PDF]

				R. L. Comenzo, P. Zhou, M. Fleisher, B. Clark, and J. Teruya-Feldstein Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins Blood, May 1, 2006; 107(9): 3489 - 3491. [Abstract] [Full Text] [PDF]

				O Leone, G Boriani, B Chiappini, D Pacini, G Cenacchi, S Martin Suarez, C Rapezzi, M.L Bacchi Reggiani, and G Marinelli Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation Eur. Heart J., July 2, 2004; 25(14): 1237 - 1241. [Abstract] [Full Text] [PDF]

				M. A. Gertz, G. Merlini, and S. P. Treon Amyloidosis and Waldenstrom's Macroglobulinemia Hematology, January 1, 2004; 2004(1): 257 - 282. [Abstract] [Full Text] [PDF]

				A. Solomon, D. T. Weiss, and J. S. Wall Therapeutic Potential of Chimeric Amyloid-reactive Monoclonal Antibody 11-1F4 Clin. Cancer Res., September 1, 2003; 9(10): 3831S - 3838. [Abstract] [Full Text] [PDF]

				G. Merlini and V. Bellotti Molecular Mechanisms of Amyloidosis N. Engl. J. Med., August 7, 2003; 349(6): 583 - 596. [Full Text] [PDF]

				R. L. Comenzo and M. A. Gertz Autologous stem cell transplantation for primary systemic amyloidosis Blood, May 29, 2002; 99(12): 4276 - 4282. [Abstract] [Full Text] [PDF]

				B. O'Nuallain and R. Wetzel Conformational Abs recognizing a generic amyloid fibril epitope PNAS, January 24, 2002; (2002) 22662599. [Abstract] [Full Text] [PDF]

				B. O'Nuallain and R. Wetzel Conformational Abs recognizing a generic amyloid fibril epitope PNAS, February 5, 2002; 99(3): 1485 - 1490. [Abstract] [Full Text] [PDF]